Method for preventing hereditary angioedema attack

A method of treating hereditary angioedema (HAE), the method comprising:

• administering to a subject in need thereof 300 mg of an antibody that binds to active plasma kallikrein,
• wherein the antibody comprises a heavy chain complementarity determining region (HC CDR) 1 set forth in SEQ ID NO:
• 5, a HC CDR2 set forth in SEQ ID NO:
• 6, a HC CDR3 set forth in SEQ ID NO:
• 7, a light chain CDR (LC CDR) 1 set forth in SEQ ID NO:
• 8, a LC CDR2 set forth in SEQ ID NO:
• 9, and LC CDR3 set forth in SEQ ID NO:
• 10,
• wherein the antibody is formulated in 30 mM sodium phosphate, citric acid, 50 mM histidine, 90 mM sodium chloride, and 0.01% Tween 80, pH 6.0, and
• the antibody being first administered for a loading period, and then for a maintenance period;
• wherein in the loading period, the antibody is administered once every week, and wherein in the maintenance period, the antibody is administered once every two to four weeks;
• wherein the subject is a human patient who has experienced at least nine HAE attacks within three months prior to the first administration of the antibody;
• and
• wherein administration of the antibody reduces cleaved kininogen of the subject to a level comparable to or below the level of healthy subjects.